Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Jan 1.

Published in final edited form as: Clin Lung Cancer. 2016 Aug 8;18(1):34–42.e2. doi: 10.1016/j.cllc.2016.07.007

Table 5.

Predose Plasma Concentrations of Insulin-like Growth Factor-1

Time point	Linsitinib + Erlotinib		Placebo + Erlotinib
Time point	N	Median (Range) ng/mL	N	Median (Range) ng/mL
Cycle 1, day 1	33	171.8 (36.9–347.4)	37	166.8 (64.6–364.3)
Cycle 2, day 1	28	244.6 (65.4–655.7)	34	161.4 (71.7–371.5)
Cycle 3, day 1	25	217.3 (112.3–511.0)	34	153.1 (65.3–318.6)
Cycle 4, day 1	21	257.3 (158.6–435.1)	35	158.7 (77.6–292.4)
Cycle 5, day 1	19	272.3 (12.3–503.3)	34	149.0 (75.2–258.7)